Democratic Republic of the Congo

Health Overview
Key Health Risks
Health Risk Callout
Other Health Risks
Regional Information
Vaccine and Malaria Prevention
- Risk Level: High
- Areas: All areas of DRC
- Recommended Drug: Atovaquone-proguanil (Malarone); doxycycline; mefloquine; tafenoquine (G6PD testing required before prescribing)
- Drug Resistance: Yes
The DRC has the highest absolute malaria case burden globally. P. falciparum is present throughout the entire country with chloroquine resistance. Malaria prophylaxis is mandatory for all travelers to any part of the country. Any febrile illness within 12 months of return from the DRC must be evaluated immediately for malaria.
Physician Note
The DRC is the most medically demanding destination on this platform, and the reason has changed since this dossier was last written. The country is in the largest Ebola outbreak it has ever recorded - Bundibugyo virus, roughly 4,700 confirmed cases and over 2,100 deaths as of mid-August, a case fatality ratio near 47%.
The clinical point that matters most: there is no licensed vaccine and no specific treatment for Bundibugyo virus. Ervebo and the Zabdeno/Mvabea regimen target Zaire ebolavirus and will not protect against this species. Anyone who believes they are covered because they have had an Ebola vaccine is mistaken.
Beyond Ebola, the DRC has the world's highest absolute malaria burden and complete chloroquine resistance. Atovaquone-proguanil is my first choice here; doxycycline is a reasonable alternative for cost-conscious Kinshasa-based travelers. Meningococcal disease is active in Kongo Central - MenACWY plus MenB before departure. Clade I mpox is more severe than the clade seen in the 2022 global outbreak.
Practically, the 21-day US re-entry restriction reshapes every itinerary. Healthcare outside Kinshasa does not exist; Clinique Ngaliema is the reference point in the capital and evacuation to Johannesburg is the realistic plan. Be sure to consult your Dr. prior to travel to discuss
Pre-Departure Checklist
8+ Weeks
- State Dept Level 4 - Do Not Travel, entire country (issued 15 July 2026). Settle whether this trip should proceed at all before booking anything.
- US re-entry restriction: anyone who has been in the DRC within 21 days cannot board a US-bound commercial flight. Plan on 21 days outside the DRC before flying home.
- Be sure to consult your Dr. prior to travel to discuss
- CDC recommends Yellow fever vaccine (required - 10-day lead required; Bring the card)
- Meningococcal vaccine (MenACWY and MenB given active outbreak)
- Hepatitis A complete series
- Hepatitis B series
- Typhoid
- Polio booster
- Begin malaria prophylaxis consultation
- Consider rabies pre-exposure series if wildlife or animal exposure anticipated
- JYNNEOS mpox vaccine if eligible and at risk.
2-4 Weeks
- Confirm medevac insurance with named provider - and confirm in writing whether the policy covers suspected viral haemorrhagic fever
- Cholera vaccine if indicated
- Obtain doxycycline or atovaquone-proguanil prescription
- Assemble field medical kit
- Bring all medications from home in original packaging with prescriptions
- NOTE: Ebola Bundibugyo virus outbreak active across six provinces - Ituri, North Kivu, South Kivu, Haut-Uele, Tshopo and Bas-Uele. CDC advises reconsidering nonessential travel to Ituri, North Kivu and South Kivu (Level 3) and enhanced precautions elsewhere in the DRC (Level 2). No vaccine protects against this species.
Day Of
- Start atovaquone-proguanil per schedule
- Carry yellow fever card separately from passport (required at border)
- Confirm emergency contact at Clinique Ngaliema
- Carry US Embassy emergency number
- Confirm you can remain outside the DRC for 21 days before your US-bound flight
- Ebola Bundibugyo outbreak active across six provinces - avoid contact with sick individuals, bodily fluids and funeral practices, and avoid healthcare facilities in outbreak areas for nonurgent care.
Trip Type Guidance
Mission travel: the DRC is under a country-wide State Department Level 4 Do Not Travel advisory (15 July 2026) and is in the middle of the largest Ebola outbreak in its history. Earlier guidance in this dossier treated Kinshasa and the Kasai region as workable for mission teams with the eastern provinces off-limits; that framing no longer holds. The advisory now covers the entire country, and the outbreak has spread beyond the east into Haut-Uele, Tshopo and Bas-Uele. Any team still considering deployment must account for the 21-day US re-entry restriction, which adds a three-week tail before anyone can fly home. Vetted local hosts, written medevac plans naming a provider and a receiving hospital, full prophylaxis including MenACWY and MenB, and Ebola-specific infection control protocols are minimum requirements rather than best practice.

